Compare CVS Health Corp (CVS) vs JPMorgan Chase & Co (JPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs JPMorgan Chase & Co — how do they compare? CVS Health Corp trades at $104.86 (market cap $135.48B), while JPMorgan Chase & Co trades at $343.25 (market cap $911.47B). The key difference: JPMorgan Chase & Co is far larger — about 6.7× CVS Health Corp's market cap, and CVS Health Corp pays the higher dividend (2.51%). Which is the better fit depends on your goals.
| CVS | JPM | |
|---|---|---|
Market Cap | $135.48B | $911.47B |
Sector | Health | Financials |
52-Week High | $106.18 | $342.89 |
52-Week Low | $58.75 | $282.84 |
Enterprise Value | $202.02B | — |
Dividend Yield | 2.51% | 1.75% |
Volume | — | 10,479,943 |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $105.9, up 1.68% recently, with a bullish technical signal and strong analyst support (84.6% buy ratings). The company has beaten earnings estimates for three consecutive quarters, including Q1 2026 EPS of $2.57 versus $2.18 expected. Revenue growth remains robust, reaching $402.07B in 2025, though net margins are thin at 0.72%. Recent news highlights a settlement with the FTC advancing prescription drug affordability initiatives.
The outlook is positive given earnings momentum and strategic positioning in healthcare services, but risks include regulatory pressures and margin compression. The consensus price target of $110.62 suggests modest upside from current levels, supported by dividend payments and institutional confidence.
JPMorgan Chase (JPM) trades at $334.53, down 0.58% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 and Q2 2026 earnings beats, with Q1 EPS of $5.94 versus $5.47 expected and Q2 EPS of $7.7 versus $5.59 expected, though Q4 2025 missed expectations. Revenue grew to $181.85B in 2025, with a net income margin of 31.61% and ROE of 17.03%. Analyst consensus is a Moderate Buy with a $369.67 price target, and recent news highlights CEO Jamie Dimon's economic warnings and upcoming bank earnings focus.
JPMorgan's outlook remains positive driven by earnings momentum and solid profitability, but risks include geopolitical tensions, cybersecurity threats from AI, and macroeconomic volatility cited by management. The stock offers potential upside to the consensus target, supported by institutional buying interest, though investors should weigh elevated debt levels and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →
